Currently, except for LIR and SMG, the numbers of related clinical studies of other GLP-1R agonists are few, especially in obese or overweight people without diabetes
While this research has the potential to impact people with T2D, as they would benefit directly from a long-acting GLP-1 drug product that can reduce treatment burden and improve disease management, numerous recent studies suggest that such a product can improve the quality of treatment for people with obesity or T1D as well ( 17, 6870 )
This treatment will not out work an unhealthy lifestyle but gives exceptional results when used alongside a healthy diet and regular exercise regime.
The product is classified as a health supplement under Singapore's HSA Health Products Act and is not a pharmaceutical drug
For men on ongoing TRT, continuous HCG use maintains consistent testicular support
In the SURPASS clinical trial program for type 2 diabetes (Mounjaro), constipation was reported in approximately 12-17% of patients across the 5 mg, 10 mg, and 15 mg weekly doses, with higher rates generally observed at higher doses
